India to get first protein manufacturing plant?

Related tags Pharmacology Biotechnology India

US-based biotechnology company Human Genome Sciences is planning to
set up the first protein manufacturing facility in India in
collaboration with local companies.

The company's chief executive William Haseltine told the country's Financial Express newspaper that India has the capacity to capture almost a quarter of the global pharmaceutical business.

India is already emerging as a powerhouse in the production of chemical pharmaceutical ingredients, filing a third of all the Drug Master Files for active pharma ingredients (APIs) received in the US last year. But the country's has not seen any significant investment to date in biologics production.

Haseltine told a meeting to mark the opening of a new clinical research facility by Indian firm Nicholas Piramal that the company was looking beyond a manufacturing alliance in the country and is also interested in in- and out-licensing products.

Almost a third of $40-$50 billion (€33-€41bn) spend by global pharma firms could come into India from 2010, provided the regulations were in place, he added.

In order to achieve its potential in biotech, India will have to overcome some significant barriers, including a confused regulatory environment, uncertainties about intellectual property protection and the slow pace of integration between academic and commercial science.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars